One of the biggest challenges in oncology is treatment resistance, a phenomenon that undermines the effectiveness of cancer therapies and leads to poor patient outcomes. When cancer cells become resistant to drugs or radiation, standard treatments fail to halt disease progression, necessitating a deeper understanding of the underlying mechanisms. Scientists are actively investigating how acquired resistance develops, often through genetic mutations, tumor microenvironment changes, or activation of alternative signaling pathways.
For instance, Calidi Biotherapeutics Inc. (NYSE American: CLDI) is developing oncolytic virus therapies designed to equip the immune system to recognize and attack cancer cells, potentially overcoming resistance. These viruses selectively infect and destroy tumor cells while stimulating an immune response, offering a novel approach to treatment-resistant cancers.
Other strategies include targeting drug efflux pumps, which cancer cells use to expel chemotherapy agents, and inhibiting DNA repair mechanisms that allow tumors to survive DNA-damaging treatments. Researchers are also exploring combination therapies that attack multiple pathways simultaneously, reducing the chance of resistance developing.
The implications of solving treatment resistance are profound: improved survival rates, reduced need for toxic second-line therapies, and better quality of life for patients. As the medical community continues to unravel the complexities of resistance, innovative treatments like oncolytic viruses and personalized medicine hold promise for more effective cancer care.
For more information, visit BioMedWire.
